AcelRx Pharmaceuticals Inc (NASDAQ: ACRX) shares leaped 11% to $3.64, after the company disclosed that its investigational product candidate ARX-04 provided solid tolerance level in an open-label Phase three trial for post operative acute pain treatment. Share volume totaled 2.9 million, compared to an all-day average of 350,000
